Comparative Pharmacology
Head-to-head clinical analysis: EXPAREL versus SCANDONEST L.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXPAREL versus SCANDONEST L.
EXPAREL vs SCANDONEST L
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, inhibiting nerve impulse conduction and providing prolonged analgesia.
Scandonest L (mepivacaine hydrochloride) is an amide-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx across the membrane, thereby blocking nerve impulse initiation and conduction.
Local infiltration: up to 266 mg (20 mL) as a single dose; interscalene brachial plexus block: up to 133 mg (10 mL); femoral nerve block: up to 133 mg (10 mL). Maximum dose 266 mg. Administer via slow injection with frequent aspiration.
Dental infiltration or nerve block: 1.3 mL of 3% solution (isocaine) per site; maximum 9 mg/kg (0.3 mL/kg) per session. Infiltration: 0.5-1.0 mL; nerve block: 1.0-1.3 mL.
None Documented
None Documented
Terminal elimination half-life is 12-48 hours (mean ~24 hours), reflecting prolonged release from the multivesicular liposome depot.
Terminal elimination half-life is 1.5–2.0 hours in healthy adults; prolonged to 3–5 hours in patients with hepatic impairment or severe renal disease.
Renal (approximately 96% as metabolites, <10% unchanged). Biliary/fecal excretion is negligible.
Primarily hepatic metabolism (approx. 90%) via amidase hydrolysis and aromatic hydroxylation; renal excretion of unchanged drug accounts for <5% of the dose; less than 1% excreted in feces.
Category C
Category C
Local Anesthetic
Local Anesthetic